Exco InTouch's Electronic Patient Diary Selected by Synairgen to Capture ePRO Data in IFN-beta Asthma Trial
Exco InTouch, a mobile messaging provider for the pharmaceutical industry, announces that its electronic patient reported outcomes (ePRO) solutions have been selected by Synairgen, a drug discovery company focused on asthma and chronic obstructive pulmonary disease (COPD).
Exco InTouch's Electronic Patient Diary Selected by Synairgen to Capture ePRO Data in IFN-beta Asthma Trial
(30 September, 2008) Exco InTouch, the leading mobile messaging provider for the pharmaceutical industry, announces that its electronic patient reported outcomes (ePRO) solutions have been selected by Synairgen, a drug discovery company focused on asthma and chronic obstructive pulmonary disease (COPD). Exco InTouch's short message service (SMS) ePRO offerings will enable Synairgen to collect patient data in its second clinical study of inhaled interferon beta (IFN-beta) for asthma treatment.
This Phase 1 study from Synairgen is designed to establish the safety of inhaled IFN-beta at four different dose levels over a 14 day period in asthmatic volunteers. Exco InTouch's innovative text messaging ePRO system will enable Synairgen to collect accurate PRO data which might be crucial in gauging the efficacy in future studies.
Using secure mobile online access, this technology will allow patients to complete diary questionnaires at pre-specified times via a series of text
messages. Secure text messages will enable Synairgen's patients to easily record and transmit data concerning their asthma using their own mobile phone, facilitating diary data collection which is then relayed back to the clinical sites for further analyses.
"Symptom diary cards are notoriously unreliable; we are attracted to this simple method for collecting asthma symptom scores on a daily basis," said Richard Marsden, Managing Director of Synairgen
About Exco InTouch's ePRO Solutions
For more complex data collection, a java application which runs on the patient's own mobile phone can be used in mobile data capture, dose titration and disease exacerbation monitoring. Simple and easy to deploy, Exco InTouch's software can be used for daily questionnaires in conjunction with the REACT compliance platform to deliver high quality data within appropriate timeframes.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
